@djvreeman
2016
Key Issues
1. Expertise and resources
2. Genetic testing
3. Sources of mapping variability
4. Maintenance
photo via Vernio77 | cc-by-sa
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
500
1000
1500
2000
2500
3000
3500
4000
Vreeman DJ, Finnell JT, Overhage JM. A rationale for parsimonious laboratory term mapping by frequency. AMIA Annu Symp Proc. 2007 Oct 11:771-5. PMID: 18693941.
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
500
1000
1500
2000
2500
3000
3500
4000
Genetic Testing
Some docket comments suggested unfamiliarity
with LOINCs approach
An evolving field
Changing reporting styles
LOINC terms reflect how data is
being reported
About 2000 terms in current
release
Deckard J, McDonald CJ, Vreeman DJ. Supporting interoperability of genetic data with LOINC. J Am Med Inform Assoc. 2015 Feb 5. PMID: 25656513.
4 Main Categories
Full mutation analysis
82534-9CASR gene full mutation analysis in Blood or Tissue by Sequencing
Deckard J, McDonald CJ, Vreeman DJ. Supporting interoperability of genetic data with LOINC. J Am Med Inform Assoc. 2015 Feb 5. PMID: 25656513.
photo via
[credit]
photo via ericmay
| cc-by-nc
Which leads to
Variations!
The Solution
1.
2.
3.
4.
5.
Other evolving
conversations
Which distinctions in specimen are
clinically relevant
At what level should we make
distinctions among PCR-based methods
Other Sources
of Variation
Method vs methodless terms
Mass vs substance reporting
Similar specimens
Stay up to date
LOINC recommends
that users update to
the current version of
LOINC within 90 days
of its publication.
Why?
The most recent release is always our best
release ever.
The world moves fast.
Maximize the potential benefit of
standardized data.
Review commentary
Review commentary
Check the alternatives
Review commentary
Check the alternatives